For many years, scientists from the University of Silesia have been conducting research whose results contribute to development of medicine. These actions include designing new chemical compounds, combined with the analysis of their properties. A good example is the new quinazoline derivatives developed by Dr Eng. Jacek Mularski, Dr Katarzynę Malarz, and Prof. Robert Musioł from the University of Silesia. These compounds are used for modulating the activity of protein kinases – a large group of enzymes responsible for regulating a number of metabolic processes and pathways in human and animal cells. Such designed quinozaline derivatives can be applied for the production of anti-cancer drugs, to be used particularly in the treatment of colonic cancer, prostate cancer, as well as myeloid leukemia. This is due to the fact that the compounds blocking the activity of kinases allow to obtain high-selectivity drugs, which means that the active substances present therein reach the pathologically affected cells, without damaging the healthy cells at the same time.
The new quinozaline derivatives and their application have been covered by patent protection.